<DOC>
	<DOC>NCT02215499</DOC>
	<brief_summary>This study is being conducted to evaluate the safety, tolerability, blood distribution and effectiveness single ascending doses of JZP-386 compared to doses of XyremÂ® and placebo.</brief_summary>
	<brief_title>A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics</brief_title>
	<detailed_description>This is a Phase 1, single center, single-ascending dose, sequential, randomized, and crossover study. Following a Screening period of up to 21 days, eligible subjects will be randomized different dosing sequences, with approximately 4 subjects allocated to each dosing sequence. The total in-clinic duration for each subject will be 24 days (including the admission day prior to the first dosing period).</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Healthy male and female volunteer subjects, 18 to 50 years of age, inclusive. Clinically significant history of unstable medical abnormality. Inability to cooperate with study procedures. Female subjects with a positive pregnancy test result, nursing or lactating. Participation in any other investigational drug trial within 90 days prior to screening. A history of prescription drug abuse, or illicit drug or known drug dependence within last 5 years prior to screening. Use of any prescription medication within 14 days prior to dosing. A history of alcohol abuse or dependence.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>JZP-386, Xyrem, sodium oxybate</keyword>
</DOC>